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Abstract
NOTCH1 is involved in the pathogenesis of T-acute lymphoblastic leukemia (T-ALL) carrying the very rare translocation
t(7;9)(q34;q34.3).
We analyzed the expression of genes belonging to NOTCH pathway, in acute leukemia primary samples and lymphoblastoid
cell lines. NOTCH1 pathway activation represents a common feature of T-ALL when compared to acute myelogenous
leukemia (AML) and B-cell precursor acute lymphoblastic leukemia. The contemporary expression of NOTCH1 and its ligands
on cell surface contributes to high levels of pathway activity. AML primary samples show high levels of JAGGED1 expression
despite the low NOTCH1 pathway activation, consistent with an autonomous JAGGED1 signaling in myeloid leukemogenesis.
q 2004 Elsevier Ireland Ltd. All rights reserved.
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NOTCH gene family encodes single pass trans-
membrane receptors able to transduce intercellular
signals involved in cell-fate determination [1].
NOTCH1 signal is triggered by the Delta/Serrate/
Lag2 (DSL) ligands [1]. The DSL family of genes
include the vertebrate homologues JAGGED1,
JAGGED2, DLL-1 [1], DLL-3 and DLL-4 [2].0304-3835/$ - see front matter q 2004 Elsevier Ireland Ltd. All rights re
doi:10.1016/j.canlet.2004.07.022
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025 033 0411.
E-mail address: raffaella.chiaramonte@unimi.it (R. Chiaramonte).NOTCH pathway plays a role in haematopoiesis
affecting both stem cells and committed progenitors
[3]. The expression of NOTCH1 and its ligands in
thymic stromal cells and in developing thymocytes is
consistent with NOTCH function. NOTCH1 is turn on
before T-cell commitment along the lymphoid
development; a variety of model systems indicates
that NOTCH1 signaling is required for the earliest
stages of T-cell commitment in the thymus and that, in
its absence, cells develop toward the B-lineage [4].
NOTCH1 regulates myeloid cells differentiation
and safeguards them from apoptosis [5]. In myeloid
environment, JAGGED1 appears to play a critical
role as its enforced expression causes the loss of cellCancer Letters 219 (2005) 113–120www.elsevier.com/locate/canletserved.
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GM-GSF [6].
The fundamental role played by the NOTCH
pathway in T-lineage proliferation and differentiation
has a counterpart in the involvement of NOTCH
signaling alterations in the pathogenesis of T-cell
acute lymphoblastic leukemia (T-ALL). The t(7;9)
(q34;q34.3) translocation, which occurs specifically in
T-ALL, places the 3 0half of NOTCH1 gene sequence
downstream TCR-b regulative sequence [7] and leads
to the overexpression of a constitutively active
intracellular portion of NOTCH1 (NICD) [8]. This
form has been proved to be neoplastic in vivo and, if
over expressed in mouse bone marrow, to induce
selectively T-ALL [8] suggesting that NOTCH1
behaves as a gate keeping gene in the T-lineage.
Yan et al. [9] demonstrated that the induction of the
DLL-4 gene expression in bone marrow cells gives
rise to T-cell leukemia. Moreover, it has been
proposed that the ligand JAGGED1 may be respon-
sible of NOTCH activation found in T-cell-derived
anaplastic large cell lymphoma by inducing prolifer-
ation and inhibiting apoptosis [10]. Regarding
NOTCH signaling in myeloid neoplastic counterpart,
acute myelogenous leukemia is characterized by
abnormalities in the NOTCH1–JAGGED1 system
which would give rise to excessive self-renewal and
block of differentiation [11].
We have previously demonstrated that, indepen-
dently from the translocation t(7;9)(q34;q34.3), the
NOTCH pathway is activated in T-ALL cell lines when
compared to B-cell lymphomas (EBV negative) or to
normal B and T lymphocytes from healthy donors [12].
In the present study we further extend these
observations by analysing the expression of a large
panel of genes involved in NOTCH pathway activity,
in a series of primary leukemia cells isolated from
bone marrow of pediatric patients with T-ALL, B cell
precursor ALL (BCP–ALL) and AML. Our findings
reinforce the notion that NOTCH pathway over-
signaling represents a hallmark of the T-ALL since
AML and BCP–ALL showed significantly lower
levels of expression. Of note T ALL cell lines and
primary samples are both characterized by the
contemporary expression of NOTCH receptor and
its ligands supporting the hypothesis that NOTCH
pathway activation in T-ALL can be due, at least in
part, to an auto-activation of this pathway. By contrastin AML we found high levels of JAGGED1
expression despite of the low expression of
NOTCH1 pathway genes, consistent with a potential
role of autonomous JAGGED1 signaling in myeloid
leukemogenesis.2. Materials and methods
2.1. Cell cultures and blood samples
Under informed consent by the parents or the
guardians, 32 children with T-ALL, 25 with B-cell
precursor ALL and 20 with AML were included in the
study. All patients have been referred to a single
Institution (Clinica Pediatrica of Monza, Italy)
and treated according to the protocols of the
‘Associazione Italiana Ematologia ed Oncologia
Pediatrica’ (AIEOP). Diagnoses have been made
according to standard morphological, immunological
and molecular genetics criteria. Peripheral blood
mononuclear cells (PBMC) have been separated on
Ficoll-Hypaque gradient, frozen as viable cells and
kept at K80 8C. Mononuclear cells isolated from
peripheral blood of healthy volunteers were used as
controls. The following T-ALL cell lines, Jurkat,
SupT1, MOLT4, CEM, HuT78, RPMI-8402, FRO
and KE37, and B-cell derived leukemia/lymphoma
cell lines, BC2, Raji, AS283, VAL, Daudy, BL135,
BL41, EW36, Ly8, were used. Cell lines were
cultured as previously reported [12] in 5% CO2
atmosphere in complete RPMI-1640 medium
supplemented with 10% foetal calf serum.
2.2. Retrotranscription and amplification
Total RNA was extracted according to Chomc-
zynski and Sacchi [13]. RNA samples were retro-
transcripted by M-MLV Reverse Transcriptase
(Gibco BRL-Life Technologies) in the conditions
suggested. PCR was performed in a 20 ml reaction
mixture containing 2 ml of cDNA, 1! PCR Buffer II,
1.5 mM MgCl2, 200 mM dNTPs, 0.25 units of Ampli-
Taq DNA Polymerase (Perkin–Elmer Corporation).
Amplifications were performed for the number of
cycles specified in Table 1 according to the following
regime: denaturation at 94 8C for 30 s, annealing at
57 8C for 30 s and extension at 72 8C for 30 s.
Table 1
PCR primers and number of cycles performed for each amplification
NOTCH1 (22 cycles) Fwd CCCACTCATTCTGGTTGTCG HES5 Fwd AGAAAAACCGACTGCGGAAG
Rev CGCCTTTGTGCTTCTGTTCT (26 cycles) Rev GACAGCCATCTCCAGGATGT
JAGGED1 (25 cycles) Fwd GTCGGTCTTCCAGTCTCCAG IFI-16 Fwd CCAGCTTTTCTGCTTTCGAC
Rev TGATTTCCTTGATCGGGTTC (24 cycles) Rev GTTGGTGGCATCTGAGGAGT
JAGGED2 (25 cycles) Fwd AATGGTGGCATCTGTGTTGA MNDA Fwd CAAGCAAGCATCTGGAACAA
Rev GCGATACCCGTTGATCTCAT (25 cycles) Rev AGCTTGCGGTCAACTGTTCT
DLL-1 (26 cycles) Fwd TATCCGCTATCCAGGCTGTC MELTRINb Fwd TGCAGGAACACCTCCTTCTT
Rev GGTGGGCAGGTACAGGAGTA (26 cycles) Rev CATAGGCCCACTGTCGATAC
DLL-3 (23 cycles) Fwd TCCCAGAATTTCAAACCCAA Id3 Fwd ACTCAGCTT GCCAGGTGGA
Rev TCACCTCCAATCTGGTCTCC (23 cycles) Rev AAGCTCCTTTTGTCGTTGGA
DLL-4 (25 cycles) Fwd ACTACTGCACCCACCACTCC HERP2 Fwd AACTGTTGGTGGCCTGAATC
Rev CCTGTCCACTTTCTTCTCGC (26 cycles) Rev GCTGGTAAATGCAGGCGTAT
HES1 (23 cycles) Fwd ACGACACCGGATAAACCAAA DELTEX Fwd CTTCCCTGATACCCAGACCA
Rev CGGAGGTGCTTCACTGTCAT (24 cycles) Rev CGTGCCGATAGTGAAGATGA
pTa (23 cycles) Fwd CTGGATGCCTTCACCTATGG GAPDH Fwd CCATGGAGAAGGCTGGGG
Rev CAGGTCCTGGCTGTAGAAGC (20 cycles) Rev CAAAGTTGTCATGGATGACC
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electrophoresis in the presence of ethidium bromide
(100 ng/ml). Results of electrophoresis were acquired
by the image acquisition system EDAS 2400 (Kodak)
and following analysed by Kodak 1D image analysis
system.Fig. 1. RT-PCR analysis of DSL ligands expression in T-ALL cell
lines; EW36 B cell line and PBMC have been used as control for
JAGGED1, JAGGED2, DLL-1, DLL-3, DLL-4. To verify the
specificity of the reactions, parallel amplifications have been
performed on genomic DNA resulting in amplified DNA fragments
of different size (not shown). The house keeping gene GAPDH has
been used for normalization.2.3. Statistical analysis
All values resulting from image analysis of PCR
products were normalized against the corresponding
values obtained from GAPDH amplification. The
resulting values were then statistically analysed by
ANOVA (analysis of variance) test to reveal if there is
any statistical difference in gene expression associated
with the different leukemia cell samples, T-ALL,
BCP–ALL and AML. Analysis was independently
performed for each gene. The tested hypothesis was:
H0Zgene expression values are equal across the
different cell types; versus
H1Zat least two cell types gene expression values
are different.
The rejection of the null hypothesis (H0)
(P-value!0.01) drives to the conclusion that the
analysed gene expression levels are different in, at
least, two among the analysed populations. A
following multiple comparison test (Tukey test) was
performed to determine which particular population
differs from the others: the difference between values
distributions of two samples groups is significant
when P!0.05; is not significant when PO0.05.3. Results
3.1. Identification of NOTCH pathway target genes
We have previously reported the concordance
between HES1 and NOTCH1 genes expression
both in T-cell ALL and B-cell lymphoma cell lines
[12]. To identify further NOTCH pathway target
R. Chiaramonte et al. / Cancer Letters 219 (2005) 113–120116genes we have expanded the analysis to the genes
reported to be modulated by NOTCH pathway: pTa
(the gene for preTCR-a), DELTEX, HERP2, HES5,
MELTRINb (an ADAM family metallo-protease), IFI-
16 and MNDA [14,15]. Only the expression of pTa
gene correlates with NOTCH1 and HES1 expression
(data not shown). Accordingly, the subsequent
analyses on primary leukemic cells were limited to
NOTCH1, HES1 and pTa as marker of NOTCH1
signaling.Fig. 2. RT-PCR analysis of Notch pathway-related genes, NOTCH1, its tar
blood samples from patients with acute leukemia T-ALL, BCP–ALL and A
controls were inserted: for the amplification of NOTCH1, HES1 and pTa po
lines, for JAGGED1and DLL-4 amplifications EW36 and MOLT4 cell line
Results of one representative experiment are reported.3.2. NOTCH1 and ligands expression in T-ALL
cell lines
To assess a possible contribution of the ligands in
the NOTCH pathway activation we performed RT-
PCR analyses on T-ALL leukemia cell lines of
transcripts for all the DSL ligands. The following
T-ALL cell lines were analysed: SupT1 carrying
t(7;9)(q34;q34.3), Jurkat, HuT78, RPMI-8402, KE37,
MOLT4, CEM, FRO. PBMC isolated from normalget genes, HES1 and pTa, and the ligands JAGGED1 and DLL-4, in
ML. To verify the specificity of the reactions, positive and negative
sitive and negative controls are, respectively, MOLT4 and BL41 cell
s. The house keeping gene GAPDH has been used for normalization.
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as controls.
As shown in Fig. 1 all T-ALL cell lines, that we
have previously assessed to be characterized by
NOTCH1 pathway activation [12], expressed one or
more NOTCH ligands encoding genes.
3.3. Expression analysis of NOTCH pathway related
genes on primary acute leukemia samples
Fig. 2 shows the representative results of RT-PCR
analysis of NOTCH1, HES1, pTa, JAGGED1 and
DLL-4 genes expression in primary ALL and
AML samples and PBMC from normal donors.
RT-PCR analysis was performed three independent
times and showed reproducible results (data not
shown).
Results of all experiments performed in 32 T-ALL,
25 BCP–ALL and 20 AML patient samples are shown
in Fig. 3. The box-plots used for presenting data showFig. 3. Median and distribution of the expression values of NOTCH relate
samples from patients with T-ALL, BCP–ALL and AML. Normalization h
been used to represent data and the median value (dark line) is reported
Results of Tukey test (multiple comparison) are reported: the difference be
P!0.05; is not significant when PO0.05.the median value (dark line) within a box containing
50% of the samples (25–75th percentile). Statistical
analyses were performed by using ANOVA and
Tukey tests. T-ALL samples showed NOTCH1 levels
of expression equivalent to AML (PO0.05), whereas
they are higher if compared to BCP–ALL (P!0.01).
With respect to NOTCH1 pathway signaling, as
measured by HES1 and pTa genes expression,
T-ALL samples showed the highest levels of
expression as compared to AML (P!0.01) and
furthermore in BCP–ALL samples (P!0.01).
Finally, the analysis of the DSL ligands expression
was performed for JAGGED1 and DLL-4. Primary
samples from both B and T-cell leukemia showed
comparable levels of mRNA expression. AML
samples displayed the highest levels of JAGGED1
gene expression if compared to T-ALL (P! 0.01) and
BCP–ALL (P!0.05). No differences were detected in
the three different leukemia subgroups with respect to
DLL-4 gene expression (data not shown).d genes (NOTCH1, HES1, pTa and JAGGED1) measured in blood
as been performed against GAPDH gene expression. Box-plots have
within a box containing 50% of the samples (25–75th percentile).
tween values distributions of two samples groups is significant when
R. Chiaramonte et al. / Cancer Letters 219 (2005) 113–1201184. Discussion
During T-cell lineage development NOTCH1
expression is finely regulated [16]: NOTCH1 drives
cell fate decision (the choice between TCRg/d or a/b
and between CD4C or CD8C) by inductive inter-
actions from thymic stromal cells [17]; its expression
is physiologically down-regulated to permit success-
ful maturation by interfering with TCR signal strength
[18]. NOTCH1 seems to play a role in differentiation
also through its ability to affect cell proliferation by
modulation of cell cycle [19] with the consequent
accelerated progression through G1 phase: by main-
taining cells in a proliferative state NOTCH1 signal-
ing may interfere with differentiation. Furthermore,
during T-cell lineage development, NOTCH1 plays a
role in rescuing cells from apoptosis [20]. The present
study confirms and further extends the role of the
signaling driven by NOTCH1 and its ligands inFig. 4. A scheme of the possible bidirectional signaling of Notch1/DSL li
signaling and the transcription of target genes; on the contrary the high leve
signaling, even if NOTCH1 is expressed on these cells, possibly because o
decreased binding affinity; on the other side in AML cells the signaling star
might contribute to leukemogenesis. In BCP–ALL low levels of both N
neoplasia. The interaction between NOTCH1and the DSL ligands, here rep
driving to an autocrine signaling.the pathogenesis of different types of acute leukemia:
T-ALL, BCP–ALL and AML. We show that
high levels of NOTCH1 gene expression represent
a common feature of T-ALL independently from
the presence of the t(7;9)(q34;q34.3) translocation
observed in less than 1% patients.
It has been suggested that the oncogenic ability
of NOTCH1 truncated form may be due to the
observed failure of NOTCH1 pathway down-regu-
lation at the DP stage of T lineage development
leading to a differentiation block at intermediate
stages and malignant transformation proper of
T-ALL [18]. The widespread over-signaling of
NOTCH1 pathway relieved in T-ALL suggests
that NOTCH pathway deregulation may represent
a common way by which different genetic altera-
tions lead to the deregulation of thymocytes
development and to leukemogenesis. Recent evi-
dences further support the hypothesis that severalgands. In T-ALL Jagged1, or other DSL ligands, activate NOTCH1
ls of JAGGED1 in AML do not produce the activation of NOTCH1
f a lack of sensibility of NOTCH1 to JAGGED1-induction due to a
ting from the PDZ domain of JAGGED1, reported from other work,
OTCH1 and JAGGED1suggest they do not play any role in this
resented on different cells, might also take place inside the same cell
R. Chiaramonte et al. / Cancer Letters 219 (2005) 113–120 119oncogenes, as IKAROS dominant negative form,
BMP2, the bHLH transcriptional regulators, TAL1,
TAL2, LYL1, BHLHB1 and LMO may play their
well-assessed role in T-ALL genesis by acting
upstream NOTCH1 pathway [21–24].
A possible role for NOTCH ligands in inducing
high level of pathway activity was assessed through
the analysis of JAGGED1 and DLL-4 transcription
levels in acute leukemia blood samples. Both
ligands were selected since DLL-4 overexpression
in mouse bone marrow results in T Cell leukemia
[9]. Moreover, JAGGED1 expression in stromal
cells of bone marrow and thymus seems to drive
haematopoietic differentiation by interacting with
NOTCH1 in haematopoietic progenitors [6].
Finally, a possible role for JAGGED1 has
been suggested for T-cell-derived anaplastic
large cell lymphoma [10] and acute myelogenous
leukemia [11].
We have found that JAGGED1 is highly expressed
only in AML samples, thus confirming a selective role
of this ligand in AML [11]. By contrast, DLL-4
generally showed low levels of expression without
any evident differences among the different leukemia
subgroups.
The high level of JAGGED1 expression suggests
that this ligand might be important per se and not
necessarily in relation to NOTCH pathway activation,
according to the data recently reported by Ascano
et al. [25] who demonstrated the existence of a
NOTCH-independent pathway driven directly by
JAGGED1: a scheme of NOTCH1/DSL ligands
signaling in acute leukemia is reported in Fig. 4.
In conclusion the expression analysis of genes
involved in NOTCH1 signaling suggests that
NOTCH1 pathway exerts a wide role in acute
leukemia. More specifically in T-ALL, its function
is not restricted to those cases carrying the
t(7;9)(q34;q34.3) translocation, due to its central
role in driving cell development. In AML our findings
suggest a possible autonomous role of JAGGED1 in
supporting AML growth.Acknowledgements
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